D64.4 Congenital dyserythropoietic anemia

Name of the Condition

• Congenital dyserythropoietic anemia
• ICD Code: D64.4

Summary

Congenital dyserythropoietic anemia is a rare genetic disorder characterized by abnormal red blood cell production in the bone marrow, leading to anemia. The condition involves ineffective erythropoiesis, where red blood cell precursors fail to mature properly, resulting in reduced red blood cell count and hemoglobin levels. Symptoms typically manifest in childhood or early adulthood and may vary in severity depending on the subtype.

Causes

The condition is caused by genetic mutations that disrupt normal red blood cell development in the bone marrow. These mutations affect the maturation process of erythroid precursors, leading to abnormal cell division and morphology. Inherited in an autosomal recessive pattern, specific genetic defects vary by subtype, with mutations in genes such as CDAN1, C15ORF41, or SEC23B identified in different forms.

Risk Factors

• Family history of congenital dyserythropoietic anemia
• Consanguinity (parents who are closely related)
• Genetic mutations in erythroid development genes
• Certain ethnic populations with higher prevalence of specific subtypes

Symptoms

• Fatigue and weakness due to anemia
• Shortness of breath, especially with exertion
• Pale or jaundiced skin
• Splenomegaly (enlarged spleen)
• Jaundice or dark urine
• Gallstones (cholelithiasis)
• Skeletal abnormalities (e.g., hand/foot deformities in some subtypes)

Diagnosis

Diagnosis involves a complete blood count (CBC) to assess anemia and red blood cell morphology, followed by bone marrow biopsy to evaluate erythroid precursors. Peripheral blood smears may show abnormal red blood cell shapes, while genetic testing can identify specific mutations. Additional tests, such as hemoglobin electrophoresis or iron studies, may be performed to rule out other causes.

Treatment Options

Treatment focuses on managing anemia and complications. Blood transfusions may be necessary for severe anemia, while iron chelation therapy addresses iron overload from repeated transfusions. Splenectomy is considered for splenomegaly or hypersplenism. Hematopoietic stem cell transplantation may be an option for severe cases, particularly in younger patients.

Prognosis and Follow-Up

Prognosis varies by subtype and severity, with some individuals experiencing mild symptoms and others requiring ongoing management. Regular monitoring of hemoglobin levels, iron stores, and organ function (e.g., liver, spleen) is essential. Long-term follow-up includes surveillance for complications like iron overload or gallstones, with adjustments to treatment as needed.

Complications

• Iron overload (from transfusions)
• Gallstones (cholelithiasis)
• Splenomegaly or hypersplenism
• Skeletal abnormalities (in specific subtypes)
• Increased risk of infections (due to anemia)
• Delayed growth or development (in severe cases)

Lifestyle & Prevention

• Balanced diet to support overall health (no specific dietary restrictions unless iron overload is present)
• Avoidance of unnecessary medications that may worsen anemia
• Regular physical activity as tolerated to maintain strength
• Genetic counseling for families with a history of the condition

When to Seek Professional Help

Seek medical attention if symptoms worsen, such as increased fatigue, shortness of breath, or jaundice. Prompt evaluation is needed for signs of severe anemia, unexplained bleeding, or new complications like gallstones or infections.

Tips for Medical Coders

• Code D64.4 is specific to congenital dyserythropoietic anemia and should not be used for other anemia types.
• Documentation should specify the subtype (e.g., type I, II, or III) if known, as this may impact clinical management.
• Ensure differentiation from acquired dyserythropoietic anemia, which is coded separately.
• Verify that genetic testing or bone marrow findings support the diagnosis when available.